ANNEX I GENERAL COMMON SPECIFICATIONS, Regulation (EU) 2022/1107

In forcesince 4 Jul 2022

[This requirement shall not apply to devices covered by Tables 1 and 2 of Annex XIII.]

Performance characteristics | Requirement

All performance characteristics set out in Section 9.1, points (a) and (b), Section 9.3 and Section 9.4, point (a), of Annex I to Regulation (EU) 2017/746 |

1.

The determination of performance characteristics shall be carried out in direct comparison with a state-of-the-art device. The device used for comparison shall be one bearing CE marking, if on the market at the time of the performance evaluation.

2.

Devices used for determination of status of specimens used in determination of performance characteristics shall be state-of-the-art devices bearing CE marking.

3.

If discrepant results are identified as part of determination of performance characteristics, these results shall be resolved as far as possible, by one or more of the following:

by evaluation of the discrepant specimen in further devices,

by use of an alternative method or marker,

by a review of the clinical status and diagnosis of the patient,

by the testing of follow-up specimens.

4.

The determination of performance characteristics shall be performed on a population equivalent to the European population.

Whole system failure rate |

5.

As part of the required risk analysis the whole system failure rate leading to false negative results shall be determined in repeat assays on low-positive specimens.

Analytical sensitivity and analytical specificity, interference |

6.

For devices intended for use with plasma the manufacturer shall verify the performance of the device using all anticoagulants which the manufacturer indicates for use with the device, for at least 50 plasma specimens (for devices intended for detection and/or quantification of infectious agents, 25 positive and 25 negative).

Analytical and diagnostic specificity, interference and cross-reactivity |

7.

The manufacturer shall select the potential interfering substances to be evaluated taking account of the composition of the reagents and configuration of the device.

Batch-to-batch consistency |

8.

For devices intended to detect antigens and antibodies, the manufacturer’s batch testing criteria shall ensure that every batch consistently identifies the relevant antigens, epitopes, and antibodies and is suitable for the claimed specimen types.

9.

The manufacturer’s batch release testing for first-line assays shall include at least 100 specimens negative for the relevant analyte.

[This requirement shall not apply to devices referred to in Tables 4, 5 and 6 of Annex XIII.]

Performance characteristic | Requirement

Analytical and diagnostic sensitivity |

10.

Devices intended by the manufacturer for testing body fluids other than serum or plasma, e.g. urine, saliva, etc., shall meet the same requirements as serum or plasma devices. The manufacturer shall test specimens from the same individuals in both the devices to be approved and in a respective serum or plasma device.

11.

Devices for self-testing shall meet the same requirements as respective devices for professional use.

12.

Positive specimens used in the performance evaluation shall be selected to reflect different stages of the respective disease(s), different antibody patterns, different genotypes, different subtypes, mutants, etc.

13.

Seroconversion panels shall start with a negative bleed(s) and shall have narrow bleeding intervals as far as possible. Where this is not possible, manufacturers shall provide a justification in the performance evaluation report.

14.

For devices intended by the manufacturer to be used with serum and plasma the performance evaluation must demonstrate serum to plasma equivalency. This shall be demonstrated for at least 25 positive donations.

15.

For devices detecting or quantifying antigens or nucleic acids, the target antigen(s) or target nucleic acid region(s) respectively shall be specified in the instructions for use.

16.

For devices detecting or quantifying antibodies against an infectious agent, the target antigen(s) of those antibodies shall be specified in the instructions for use.

Analytical and diagnostic specificity |

17.

Devices intended by the manufacturer for testing body fluids other than serum or plasma, e.g. urine, saliva, etc., shall meet the same requirements as serum or plasma devices. The performance evaluation shall test specimens from the same individuals in both the devices to be approved and in a respective serum or plasma device.

18.

Devices for self-testing shall meet the same requirements as respective devices for professional use.

19.

Negative specimens used in a performance evaluation shall be defined so as to reflect the target population for which the device is intended, such as blood donors, hospitalised patients, pregnant women, etc.

20.

Specificity shall be based on repeatedly reactive false positive results in specimens negative for the target marker.

21.

For devices intended by the manufacturer to be used with serum and plasma the performance evaluation must demonstrate serum to plasma equivalency. This shall be demonstrated for at least 25 negative donations.

Analytical and diagnostic specificity, interference and cross-reactivity |

22.

The manufacturer shall include specimens such as, where applicable:

specimens representing related infections,

specimens from multigravida, i.e. women who have had more than one pregnancy, or rheumatoid factor (RF) positive patients,

specimens containing human antibodies to components of the expression system, for example anti-E. coli, or anti-yeast.

Performances obtained by lay persons |

23.

Relevant parts of the performance evaluation shall be carried out (or repeated) by appropriate lay persons to validate the operation of the device and the instructions for use. The lay persons selected for the performance evaluation shall be representative of the intended users groups.